Tirzepatide vs. Semaglutide — what the only direct trial shows.
SURMOUNT-5, published in the New England Journal of Medicine in 2025, is the only randomized controlled trial that has compared tirzepatide (Zepbound) and semaglutide (Wegovy) head-to-head for obesity. The numbers are not subtle — and they answer the question patients ask us every day.
One trial. Two drugs. 751 patients. 72 weeks.
SURMOUNT-5 randomized 751 adults with obesity 1:1 to receive maximum tolerated dose of either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), once weekly subcutaneously, for 72 weeks. Both arms received the same lifestyle counseling. The trial design eliminates almost every confound that makes cross-trial comparisons unreliable.
The primary endpoint was percent change in body weight at week 72. The result:
One receptor versus two receptors.
Semaglutide activates one receptor: GLP-1. Tirzepatide activates two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). That second receptor — GIP — does three things that explain the SURMOUNT-5 result:
- Improves insulin sensitivity independent of GLP-1, which means greater glycemic effect at the same level of appetite suppression.
- Modulates lipid metabolism — favors fat oxidation and lipid storage shifts.
- Reduces nausea compared to pure GLP-1 agonism. Counterintuitively, the dual agonist is often better tolerated than the single — patients can stay on therapeutic dose longer.
The gain is not free. Tirzepatide's GIP component is also why response varies — some patients are GIP-resistant for poorly understood reasons and lose only modestly more on tirzepatide than they would on semaglutide. We see this in clinic. It is one of the few clinical scenarios where a six-month trial-and-switch is reasonable.
How many patients hit each loss threshold.
Mean weight loss is one number. Distribution is another. SURMOUNT-5 also reported the share of patients hitting each clinical milestone — the kind of question patients actually ask: "What are the odds I lose 25%?"
| Threshold reached at week 72 | Tirzepatide arm | Semaglutide arm |
|---|---|---|
| ≥ 10% weight loss | 82% | 65% |
| ≥ 15% weight loss | 65% | 40% |
| ≥ 20% weight loss | 48% | 27% |
| ≥ 25% weight loss | 32% | 16% |
Approximate values rounded from SURMOUNT-5 published thresholds. Source: NEJM 2025.
Translation: roughly twice as many patients hit ≥25% weight loss on tirzepatide as on semaglutide. If your target is large weight loss, the math is decisive.
Waist circumference, side effects, and discontinuation.
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Mean waist circumference reduction | −18.4 cm | −13.0 cm |
| Discontinuation due to GI side effects | 2.7% | 5.6% |
| Mean A1c reduction (when applicable) | Larger | Smaller |
| Cardiovascular outcomes data | SURPASS-CVOT pending | SELECT positive (MACE benefit) |
Two notes worth pulling out:
- Tolerability is better on tirzepatide. Twice as many patients on semaglutide discontinued because of GI side effects. This is the GIP component working.
- Cardiovascular outcomes is where semaglutide still wins. The SELECT trial showed semaglutide reduces major adverse cardiovascular events (MACE) by 20% in patients with established cardiovascular disease. Tirzepatide's outcomes trial (SURPASS-CVOT) has not yet read out. For a patient with prior MI, established CAD, or prior stroke, semaglutide currently has the stronger evidence base for "this drug saves lives," not just "this drug moves weight."
How we actually pick at Limitless.
The SURMOUNT-5 result is decisive on weight loss, but in practice the choice depends on three patient-specific factors:
- Goal weight loss. If the target is >15% loss, tirzepatide is the default. If the target is 8–12% (which is enough to remit prediabetes, normalize hypertension, and reverse fatty liver in many patients), either drug can work.
- Cardiovascular history. Patient with established ASCVD, prior MI, prior stroke, or heart failure: semaglutide gets serious consideration because of SELECT. We discuss the tradeoff explicitly.
- Insurance and pricing. Coverage is patient-specific and changes monthly. Both drugs have manufacturer savings programs. We work with each patient on what is actually fillable at their pharmacy at their out-of-pocket budget.
Less common: known GIP-resistance patterns (uncommon), prior intolerance of one drug, or patient preference based on anecdote. We try to anchor decisions on the data and the labs, not on TikTok.
The limitations of head-to-head data.
- SURMOUNT-5 was not blinded in the strictest sense — patients knew which drug class they were on. Lifestyle effort can subtly differ.
- Maximum tolerated dose was used, which means responders self-selected upward. In clinic we titrate based on response and tolerance, not always to the maximum.
- Discontinuation effects were not the focus. What happens after you stop is a different conversation, and the data is sobering on both drugs (typically 2/3 of weight is regained within 12 months without lifestyle architecture).
- Lean mass change was not the primary endpoint. Both drugs cause some lean mass loss; mitigation requires resistance training and adequate protein. We program this into every protocol.
Tirzepatide vs. semaglutide, asked and answered.
- If tirzepatide wins on weight loss, why would I ever choose semaglutide?
- Cardiovascular outcomes evidence (SELECT — semaglutide reduces MACE 20% in established CV disease). Cost and access in some payer scenarios. Personal tolerability differences. Patients with low-target weight loss and CV history often choose semaglutide. Most patients without CV history starting today choose tirzepatide.
- Can I switch from semaglutide to tirzepatide?
- Yes — and many patients do. We typically wash out for one weekly cycle and start tirzepatide at 2.5 mg, titrate up based on tolerance. Real-world response after switching is usually meaningful, though not always equal to starting tirzepatide naive.
- What about Ozempic? Or Mounjaro?
- Ozempic and Wegovy are the same molecule (semaglutide), branded for type 2 diabetes versus obesity respectively. Mounjaro and Zepbound are the same molecule (tirzepatide), with the same dual branding. The drug is the same; the FDA-approved indication and pricing differ. Off-label use is common but creates insurance and supply-chain complexity we navigate at intake.
- Should I wait for retatrutide?
- For most patients, no. Retatrutide is investigational and unlikely to launch before late 2027. The current generation works. Starting now and switching later is a reasonable approach.
- What about compounded semaglutide or tirzepatide?
- FDA shortage status changed compounding access throughout 2024–2025. As of May 2026, semaglutide and tirzepatide are no longer in shortage and compounded versions are not legally available through 503A pharmacies. We prescribe FDA-approved branded product only. Patients who have been on compounded versions need to transition.
- Can I do this if I have a thyroid history?
- Both drugs carry a black-box warning for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. We screen for this at intake. Hashimoto's hypothyroidism is not a contraindication.
Continue the weight-loss series.
The right drug is the one matched to you.
We design protocols on the basis of labs, goals, history, and tolerability — not algorithms. Tirzepatide for most. Semaglutide when CV protection is the priority. Both layered into a comprehensive metabolic plan.
Request a consultation